EWTX
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (EWTX) has 3 SEC Form 4 filings (15 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 2, 2026.
Insiders have net sold $11.3M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Kevin Koch
- Employees:117
- HQ:Boulder, CO, US
- IPO:2021-03-26
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$11.3M
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$4.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Russell Alan JFirst filing | Chief Scientific Officer | Sale | 200,000 | $7.9M | Jul 2 | SEC ↗ |
Edris BadreddinFirst filing | Insider | Sale | 115,471 | $3.4M | Jan 23 | SEC ↗ |
Related companies
Edgewise Therapeutics, Inc. is in the Healthcare sector.